Tareq Abadl: Laboratory Diagnosis of Anemia
Tareq Abadl, Medical Laboratory Specialist and Director of the Blood Bank at Dr. Abdelkader Al-Mutawakkil Hospital, posted on LinkedIn:
“Laboratory Diagnosis of Anemia
1. Iron Deficiency Anemia (IDA)
When iron deficiency is suspected, several tests must be evaluated together to get the full picture:
- Hemoglobin (Hb)
The iron-containing protein that carries oxygen.
Low Hb → early indicator of anemia.
- Hematocrit (Hct)
Measures the percentage of RBCs in blood.
Low Hct → possible iron deficiency.
- Ferritin
The main iron-storage protein.
Low ferritin → strongest marker of IDA.
- Serum Iron
Measures circulating iron in blood.
Low value supports the diagnosis but not enough alone.
- Total Iron-Binding Capacity (TIBC)
In IDA, TIBC increases because the body tries to capture more iron.
- Transferrin Saturation
Low saturation → low available iron.
- RBC Indices
MCV: Low (microcytic)
MCHC: Low (hypochromic)
All these tests together give a complete assessment of iron status and confirm Iron Deficiency Anemia.
2. Hemolytic Anemia (HA)
Hemolytic anemia is a completely different mechanism—RBCs are being destroyed. Key tests include:
- Hemoglobin (Hb)
Normal or low depending on severity.
- Reticulocyte Count
Elevated retics → bone marrow trying to compensate for RBC destruction.
- Peripheral Blood Smear
Fragmented or abnormal RBCs → evidence of hemolysis.
- Bilirubin (Indirect)
Increases due to breakdown of hemoglobin.
- Haptoglobin
Decreased because it binds free hemoglobin released during hemolysis.
- LDH (Lactate Dehydrogenase)
High levels indicate cell destruction.
- Direct Coombs Test
Positive result → immune-mediated hemolysis.
These tests clarify the type, cause, and severity of hemolysis before treatment decisions.
Summary
- Iron Deficiency Anemia → Iron profile + RBC indices
- Hemolytic Anemia → Hemolysis markers + Coombs test + Reticulocytes
Combining the right tests provides accurate diagnosis and guides precise treatment.”

Follow the latest in Hemostasis Today.
-
Nov 9, 2026, 13:48PF4-ELISA–Negative HIT: Are We Missing a New Class of Anti-PF4 Immunothrombotic Disease?
-
Nov 9, 2026, 13:07Nandini Sadasivam: Gene Therapy for Sickle Cell Disease and Thalassaemia
-
Nov 9, 2026, 13:04Raising Awareness of Bleeding Disorders in Women and Girls – EHC
-
Nov 9, 2026, 12:59Rahul Bohra: Exploring the Complex Mechanisms of Sickle Cell Disease
-
Nov 9, 2026, 12:53Three Years of Movement and Thrombosis Awareness in the Czech Republic – World Thrombosis day
-
Nov 9, 2026, 12:51Octavio Marques Pontes-Neto: Intensive Blood-Pressure Control Reduces Cardiovascular Events After Ischemic Stroke
-
Nov 9, 2026, 12:49Irma Bagdoniene: What Really Makes Us Live Longer
-
Nov 9, 2026, 12:47Imo Akpan: Announcing the 2027 Women’s Hematology Summit
-
Nov 9, 2026, 12:45Shadi Yaghi: Rethinking Antithrombotic Therapy After Stroke